Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10

Chemo-immunotherapy is central to the treatment of small cell lung cancer (SCLC). Despite modest progress made with the addition of immunotherapy, current cytotoxic regimens display minimal survival benefit and new treatments are needed. Thymidylate synthase (TS) is a well-validated anti-cancer drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Gmeiner, William H., Miller, Lance D., Chou, Jeff W., Dominijanni, Anthony, Mutkus, Lysette, Marini, Frank, Ruiz, Jimmy, Dotson, Travis, Thomas, Karl W., Parks, Graham, Bellinger, Christina R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226016/
https://www.ncbi.nlm.nih.gov/pubmed/32224870
http://dx.doi.org/10.3390/cancers12040788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226016/
https://www.ncbi.nlm.nih.gov/pubmed/32224870
http://dx.doi.org/10.3390/cancers12040788

Ejemplares similares